Articles tagged "Lamivudine"

2019 American Transplant Congress
Poor Long-Term Outcome of Liver Transplant Recipients with Preexisting Renal Insufficiency
M. Sterneck¹, M. Touma¹, T. Horvatits², S. Pischke², U. Herden³, A. Lohse², L. Fischer³
¹University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Due to the MELD based allocation system the number of patients undergoing orthotopic liver transplantation (OLT) with severely impaired renal function has markedly increased.…
2015 American Transplant Congress
Replacement of Lamivudine By Telbivudine to Improve Renal Function for Post-Transplant Hepatitis B Patients – A Randomized Clinical Trial
W.-C. Lee, H.-S. Chou, R.-S. Soong, T.-J. Wu, C.-H. Cheng, Y.-C. Wang, T.-H. Wu, C.-F. Lee, K.-M. Chan.
Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan.
Background: Lamivudine is one of the anti-hepatitis B virus (HBV) agents to prevent HBV recurrence after transplantation because lamivudine is safe for long-term use. However,…
2015 American Transplant Congress
Comparison of Efficacy of Prophylactic Antivirus Therapies on Outcomes of Kidney Transplantation in Hepatitis B Virus Carriers
G. Chen, C. Wang, J. Qiu, J. Li, L. Chen.
Organ Transplant Center, The first affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Purpose To compare the efficacy between entecavir and lamivudine as prophylactic antivirus therapy on long-term outcomes of HBV carriers after kidney transplantation.Methods We retrospectively reviewed…